Sucroferric Oxyhydroxide: A Review in Hyperphosphataemia in Chronic Kidney Disease Patients Undergoing Dialysis
In conclusion, sucroferric oxyhydroxide is a valuable treatment option for hyperphosphataemia in CKD patients on dialysis, providing an effective and generally well tolerated noncalcium-based phosphate binder therapy with a lower pill burden than sevelamer carbonate and the potential for improved treatment adherence.
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Chronic Kidney Disease | Dialysis | Diarrhoea | Drugs & Pharmacology | Renvela | Study | Urology & Nephrology